Article Figures & Data
Figures
- FIGURE 1.
Overview of 18F-UCB-H synthesis (17). Reagents and conditions: a = N-tetradecyltrimethylammonium+18F-F−/tetraethylammonium+HCO3− in dimethyl sulfoxide–N,N-dimethylformamide (16), 140°C, 2 min; b = triethylamine-methanol, 60°C, 20 min; c and d = NaBH4, 60°C, 25 min. Et = ethyl group.
- FIGURE 2.
Brain uptake of 18F-UCBH after blockade with successive doses of LEV (average uptake over 60 min). %ID = percentage injected dose.
- FIGURE 3.
Time–activity curves for 18F-UCBH uptake in representative regions, with β-microprobe–derived whole-blood input function (IF) and corrected AIF (corrected for plasma-to-whole blood ratio and plasma parent fraction with population-based corrections). %ID = percentage injected dose.
- FIGURE 4.
Parent fraction curve (♦; mean ± SD; n = 4; solid line represents biexponential fit) used for correction of AIF for tracer metabolism in vivo. Additional data points (jittered for legibility) show parent fraction after LEV pretreatment (n = 4 or 5 in each group; ○, 0.1 mg/kg; △, 1 mg/kg; ●, 10 mg/kg; ▲, 100 mg/kg).
- FIGURE 5.
Example of Logan graphic analysis of 18F-UCB-H binding in hippocampal region. Main plot: ○, data points excluded from fit; ●, data points included in fit; solid line represents fit. Subplot: fit residuals.
Tables
- TABLE 1
Vt in Controls (n = 4), Reproducibility of Vt, and Blocking of 18F-UCB-H Binding by LEV
Blocking of 18F-UCB-H binding by LEV at‡: Brain region Vt (mL/cm3)* Reproducibility of Vt† 0.1 mg/kg 1 mg/kg 10 mg/kg 100 mg/kg Nucleus accumbens 10.9 ± 0.5 3.3 ± 15.0 −7.3 ± 1.4 −16.3 ± 7.1 −35.2 ± 20.4 −53.2 ± 9.0§ Amygdala 9.0 ± 0.3 3.9 ± 13.6 −8.7 ± 5.3 −16.0 ± 8.1 −33.0 ± 24.4 −49.0 ± 11.3§ Cerebellum 9.0 ± 0.2 2.2 ± 13.3 −7.4 ± 3.9 −15.6 ± 7.5 −30.2 ± 23.7 −43.8 ± 8.4ǁ Cerebral cortex 9.4 ± 0.4 3.6 ± 12.8 −10.3 ± 6.0 −16.3 ± 8.4 −33.0 ± 20.5 −48.6 ± 9.2ǁ Striatum 11.3 ± 0.5 3.3 ± 14.5 −7.6 ± 4.0 −17.1 ± 6.1 −35.1 ± 20.2 −53.5 ± 9.8§ Hippocampus 10.7 ± 0.5 3.3 ± 14.3 −9.2 ± 5.4 −15.7 ± 7.1 −34.1 ± 22.2 −52.6 ± 11.6§ Hypothalamus 9.9 ± 0.2 3.3 ± 13.2 −9.9 ± 1.3 −16.4 ± 7.7 −36.8 ± 23.3 −54.2 ± 9.0§ Medulla 8.5 ± 0.4 3.2 ± 12.1 −8.1 ± 4.5 −15.3 ± 7.1 −28.3 ± 17.5 −34.4 ± 9.2ǁ Olfactory bulbs 9.0 ± 0.2 4.4 ± 12.0 −6.8 ± 2.5 −15.0 ± 7.1 −27.4 ± 22.3 −41.9 ± 9.2ǁ Pons 8.2 ± 0.3 5.2 ± 12.4 −14.1 ± 0.2 −15.9 ± 5.4 −29.3 ± 8.7ǁ −35.2 ± 11.7§ Septum 10.5 ± 0.4 4.6 ± 18.4 −6.9 ± 6.6 −16.9 ± 7.0 −33.4 ± 21.7 −50.8 ± 10.0ǁ Thalamus 12.1 ± 0.6 2.5 ± 14.0 −10.8 ± 4.3 −16.1 ± 5.7 −36.2 ± 21.5 −55.8 ± 10.3§ Whole-brain average 9.8 ± 0.5 3.6 ± 13.1 −9.0 ± 4.6 −13.3 ± 3.3 −25.7 ± 28.0 −43.8 ± 4.7ǁ ↵* Determined by Logan graphic analysis and reported as mean ± SD.
↵† Determined as percentage difference in test–retest study and reported as mean ± SD.
↵‡ Determined by Logan graphic analysis as percentage change in Vt in test–retest study and reported as mean ± SD.
↵§ P value, determined by 1-way ANOVA and Tukey post hoc test, was less than 0.01.
↵ǁ P value, determined by 1-way ANOVA and Tukey post hoc test, was less than 0.05.
Jump to section
Related Articles
Cited By...
- Imaging of Synaptic Density in Neurodegenerative Disorders
- A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: Synthesis and preclinical characterization of [18F]SDM-16
- Imaging Synaptic Density: A Different Look at Neurologic Diseases
- Imaging synaptic density in the living human brain
- Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain